C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib

BACKGROUND AND AIM: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS One
Hauptverfasser: Hayashi, Tsuguru, Shibata, Michihiko, Oe, Shinji, Miyagawa, Koichiro, Honma, Yuichi, Harada, Masaru
Format: Artigo
Sprache:Inglês
Veröffentlicht: Public Library of Science 2020
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755182/
https://ncbi.nlm.nih.gov/pubmed/33351844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0244370
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge